Clinical Trial

A Clinical Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicular Function

Study acronym: ETNA
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate three doses of the drug leflutrozole on improvement of semen quality in men. It will also study the safety of leflutrozole. The main questions it aims to answer are: * Does leflutrozole improve semen quality? * What medical problems do participants experience when taking leflutrozole? Researchers will compare leflutrozole to a placebo (a look-alike substance that contains no drug). Participants will: * Take leflutrozole or a placebo orally once a week for 16 weeks. * Visit the clinic every 4 weeks for checkups and tests. * Provide semen samples to measure changes in semen quality. * Have their blood tested to measure hormone levels and ensure safety. * Be monitored for any side effects.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-05-19; most recent amendment 2026-02-25.
Status change: Not Yet Recruiting → Recruiting 2025-06-24
Trial Details
NCT Number NCT06993155
Lead Sponsor ReproNovo Aps
Conditions Semen Quality
Enrollment 200 participants
Start Date 2025-06-27
Primary Completion 2026-07 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-27